ATS

DigiKey Awarded Top Recognitions from Suppliers at the 2024 EDS Leadership Summit

Retrieved on: 
onsdag, maj 29, 2024
Partnership, Bourns, Digi-Key, ATS, Music

THIEF RIVER FALLS, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- DigiKey , a leading global commerce distributor offering the largest selection of technical components and automation products in stock for immediate shipment, announced that it received 18 honors from its supplier partners during the 2024 EDS Leadership Summit, held May 21-23 in Las Vegas.

Key Points: 
  • THIEF RIVER FALLS, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- DigiKey , a leading global commerce distributor offering the largest selection of technical components and automation products in stock for immediate shipment, announced that it received 18 honors from its supplier partners during the 2024 EDS Leadership Summit, held May 21-23 in Las Vegas.
  • DigiKey was recognized for its sales results, partnership, collaboration and more during the past year.
  • “We take pride in our partnerships with suppliers, which advance engineers and designers towards innovative, world-changing solutions.”
    DigiKey has expanded its portfolio in the past year by adding more than 450 new suppliers across its core business, DigiKey Marketplace and Fulfilled by DigiKey programs.
  • For more information about DigiKey’s product offerings, please visit the DigiKey website .

Stifel and Marex Announce Prime Brokerage Referral Partnership

Retrieved on: 
tisdag, maj 28, 2024
Partnership, SF, Eaton Partners, ETF, Broker-dealer, Alternative trading system, ATS, Equity, Marex, MRX, Financial services

ST. LOUIS and LONDON, May 28, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has entered into a prime brokerage services referral partnership with Marex Group plc (NASDAQ: MRX), a global diversified financial services platform, to allow both firms’ broker-dealer affiliates to better service their hedge fund and investment management clients.

Key Points: 
  • ST. LOUIS and LONDON, May 28, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has entered into a prime brokerage services referral partnership with Marex Group plc (NASDAQ: MRX), a global diversified financial services platform, to allow both firms’ broker-dealer affiliates to better service their hedge fund and investment management clients.
  • “Our sales and trading group at Stifel is primarily driven by the goal of offering our clients exceptional service coupled with unparalleled value,” said John Spensieri, Co-Head of Equity Trading at Stifel.
  • “Stifel’s multi-asset class expertise, like-minded approach to client service, award-winning research, and corporate access relationships represent a significant value-added offering for our institutional clients,” said Jack Seibald, Global Co-Head of Prime Brokerage Services and Outsourced Trading at Marex.
  • Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions.

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
torsdag, maj 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

Retrieved on: 
torsdag, maj 23, 2024
Patient, Viral, Control, American Thoracic Society, Incidence, COPD, CHIM, ATS, Chronic obstructive pulmonary disease, Viral load, Clinical trial, Infection, Vaccine

These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.

Key Points: 
  • These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.
  • The presentation, entitled “HEX17, a Novel Broad-spectrum Antiviral Intranasal Drug, Demonstrates Efficacy Against Influenza in a Controlled Human Infection Model Conducted in Healthy Adults,” was delivered by Dr Geoff Kitson, Chief Medical Officer of Pneumagen.
  • “We are very pleased to present detailed data from our Phase 2 Clinical trial of Neumifil,” said Douglas Thomson, Chief Executive Officer of Pneumagen.
  • The significant reductions in both symptoms and viral load, demonstrate the potential of this new antiviral drug not only to alleviate patients suffering but also to curtail the spread of virus within communities.

LiveRamp Announces Fourth Quarter and Fiscal Year Results

Retrieved on: 
onsdag, maj 22, 2024
Cloud, DSPS, SSPS, AMC, Google Cloud, Marketing, LiveRamp, ARR, DSP, GAAP, ATS, Comscore, Interest, Video game

SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), the leading data collaboration platform, today announced its financial results for the quarter and fiscal year ended March 31, 2024.

Key Points: 
  • A detailed discussion of our non-GAAP financial measures and a reconciliation between GAAP and non-GAAP results is provided in the schedules attached to this press release.
  • LiveRamp ended the quarter with 115 customers whose annualized subscription revenue exceeds $1 million, compared to 95 in the prior year period.
  • LiveRamp ended the quarter with 900 direct subscription customers, compared to 920 in the prior year period.
  • Fourth quarter annual recurring revenue (ARR), which is the last month of the quarter fixed subscription revenue annualized, was $467 million, up 10% compared to the prior year period.

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

Retrieved on: 
onsdag, maj 22, 2024
White lung, Patient, Survival, Data, COVID-19, American Thoracic Society, University, Therapy, ADL, Periodic breathing, Mink, Cancer, ATS, Annual general meeting, Pharmaceutical industry

These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.

Key Points: 
  • These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.
  • “New therapeutic options, like allogeneic cell therapies, are urgently needed to address the critical unmet need in immune-compromised individuals with respiratory distress.
  • Treatment: A single dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day 13.
  • Outcomes: Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS ( Hammond, T.C., Nat Commun 2024 ).

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Retrieved on: 
onsdag, maj 22, 2024
Oral medicine, Patient, Immunoglobulin E, DDW, Lung, Doctor of Philosophy, American Thoracic Society, Cytokine, Eosinophilic esophagitis, Dupilumab, Therapy, Histology, Asthma, Phase 1, STAT6, Chemokine, ATS, TPD, Gastrointestinal disease, Inflammation, Resource, HDM, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the presentation of additional preclinical data for KT-621, a potent, selective, oral heterobifunctional degrader of STAT6, at the American Thoracic Society (ATS) Annual Meeting in San Diego, California. The featured data demonstrate activity of KT-621 comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the tested cytokines, chemokines, and cell infiltrates involved in TH2 inflammation in asthma. The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab. These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases. Kymera intends to initiate Phase 1 testing for KT-621 in the second half of 2024 and expects data from the Phase 1 trial to be reported in the first half of 2025.

Key Points: 
  • The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab.
  • These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases.
  • In addition, at low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.
  • Copies of both the ATS and DDW poster presentations are available in the Resource Library section of Kymera's website.

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Retrieved on: 
onsdag, maj 22, 2024
Food, American Thoracic Society, FDA, SAN, Asthma, Conference, CNTB, Connect, Week, ATS, Poster, Entrepreneurship, FEV1, Pharmaceutical industry

presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.

Key Points: 
  • presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
  • A predefined exploratory analysis showed further improvement in lung function was achieved in patients with eosinophil levels of ≥300 cells/µl.
  • The Company has scheduled an EoP2 meeting with the FDA to discuss rademikibart’s Phase 3 regulatory path in Q2 2024.
  • A copy of the poster presentation will be made available on Connect Biopharma’s website under the “ Our Science ” section.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Retrieved on: 
tisdag, maj 21, 2024
Patient, Primary sclerosing cholangitis, TGF, Plasma, Drug, ALK5, American Thoracic Society, University, FCCP, Idiopathic disease, Therapy, PSC, SAN, Conference, Integrin, Physicalism, Idiopathic pulmonary fibrosis, Week, QLF, Biomarker, ATS, Safety, Fibrosis, IPF, ILD, Inflammation, Pharmaceutical industry

“Our 2024 ATS presentations include comprehensive clinical safety and imaging data, as well as preclinical data from our bexotegrast development program that provide further support the late-stage development of this novel therapeutic in our currently enrolling BEACON-IPF trial,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.

Key Points: 
  • “Our 2024 ATS presentations include comprehensive clinical safety and imaging data, as well as preclinical data from our bexotegrast development program that provide further support the late-stage development of this novel therapeutic in our currently enrolling BEACON-IPF trial,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • To date, in unblinded and blinded studies, bexotegrast has been administered to over 700 participants.
  • Inhibition with bexotegrast showed a distinct pharmacodynamic profile in fibrotic human PCLS compared with ALK5 inhibition.
  • In addition, no notable increases in alveolar inflammation were observed in bexotegrast-treated patients, as measured by quantitative ground glass (QGG).

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Retrieved on: 
tisdag, maj 21, 2024
Lung, Patient, Inhalation, PAH, American Thoracic Society, Therapy, Orthostatic hypertension, Safety, Conference, World Health Organization, ATS, Volunteering, Pharmaceutical industry

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA. IMPAHCT is a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multinational trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension (PAH).

Key Points: 
  • IMPAHCT is a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multinational trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension (PAH).
  • “These baseline characteristics reflect a patient population with significant disease despite treatment with two to three targeted PAH therapeutics.
  • This underscores the unmet need for novel therapeutics with unique mechanisms of action that address the key drivers of PAH,” said Hunter Gillies, MBChB, Chief Medical Officer of Aerovate Therapeutics.
  • A copy of the conference poster presentation will be available in the “Events & Presentations” section of Aerovate’s website at ir.aerovatetx.com .